Dubai, UAE / New York, USA / Istanbul, Türkiye, May 09, 2025 /24-7PressRelease/ -- Diplomatic Trade Ltd, a global trade, and investment platform operating between New York and Dubai, together with its strategic private equity arm, Diplomatic Trade Capital Group, has finalized a high-impact cross-border investment in one of Türkiye's premier pharmaceutical manufacturing and logistics groups "Farmakim ilaç Kimya Gida Ürünleri Üretim San ve Dis Tie A.S.". The transaction marks a new chapter in the evolution of healthcare manufacturing across the MENA region, bridging biotech innovation, investment banking, and IPO-readiness under one transformative initiative.

Strategic Equity Position
Diplomatic Trade Capital has acquired a controlling 49% equity position in the Turkish pharmaceutical conglomerate, securing board-level oversight and commercial rights. While financial terms remain confidential, the deal represents a significant capital deployment in alignment with long-range consolidation and growth objectives across frontier pharma markets.

UAE Biopharma Hub Launch – Q3 2025
The JV will commission a next-generation bio-manufacturing facility in the UAE by Q3 2025. The site will focus on biosynthetic therapies, regenerative compounds, and advanced life-extension pharmaceuticals designed to meet accelerating demand across Gulf states and North Africa. It will also integrate AI-driven QC, biocompatible packaging, and modular production suites aligned with EU-GMP standards.

IPO Pathway and Market Valuation
Targeting a listing in Q4 2025 on a leading UAE stock exchange, the newly formed group is currently being valued by a globally ranked Tier-1 advisory firm. Early-stage projections estimate the company's IPO valuation near $300 million USD., supported by robust EBITDA expansion, GCC distribution rights, and proprietary therapeutic pipelines.

Institutional Backing – Morgan Brookshire LLC
U.S.-based Morgan Brookshire LLC, the private family office of financier Thomas J. Kent, has structured the underlying financing through its capital markets affiliates. This injection of institutional capital marks a major transatlantic commitment to scaling critical pharma infrastructure across the Gulf and aligns with broader U.S.–GCC economic collaboration in life sciences.

Strategic Commentary
"This isn't just an acquisition—it's a launchpad for redefining pharmaceutical sovereignty and access in the region," said a Diplomatic Trade Capital spokesperson. "With UAE's policy tailwinds and healthcare reform momentum, we see this venture as a catalyst for the next decade of precision medicine, biotech IPOs, and regional supply chain independence."

The deal positions Diplomatic Trade Ltd as a key player in regional life sciences consolidation and as a pioneer in bringing institutional-grade healthcare IPOs to Middle Eastern markets.

About Diplomatic Trade Ltd & Diplomatic Trade Capital Group
Diplomatic Trade Ltd is a U.S.-registered multinational trade and investment firm with operational hubs in New York and Dubai. Through its specialized investment arm, Diplomatic Trade Capital Group, the organization focuses on cross-border joint ventures, sovereign-grade industrial projects, and emerging market IPOs. The firm is known for structuring high-impact deals across sectors including healthcare, infrastructure, clean energy, and strategic manufacturing, with a strong presence in the GCC and Africa. Its mission is to bridge institutional capital with high-growth frontier markets, leveraging deep regulatory insight and geopolitical positioning.

About the Turkish Pharmaceutical Group
The Turkish pharmaceutical conglomerate is a privately held industry leader based in Istanbul, specializing in the manufacturing, warehousing, and distribution of advanced generic drugs, biosimilars, and therapeutic compounds. With decades of operational expertise and EU-GMP-certified facilities, the company serves major public and private healthcare systems across Eastern Europe, MENA, and Central Asia. Known for its scalable production capacity and regulatory agility, the group is now expanding into biopharma and precision medicine through global partnerships and innovation-driven infrastructure.

For further information, media requests, or investment inquiries, please contact:
Dr. Benjamin Ballout
Chairman & CEO
718-709-7099
BENJAMIN.BALLOUT@DIPLOMATICTRADE.COM
WWW.DIPLOMATICTRADE.COM

This press release is distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Diplomatic Trade Ltd & Diplomatic Trade Capital Group signed an MOU to Acquire Stake in Turkish Pharma Giant "Farmakim ilaç Kimya Gida Ürünleri Üretim San ve Dis Tie A.S." Unveil $300M Biopharma.